SCCL

New Transphorm White Paper: Normally-Off D-Mode GaN Advantages Vs. Normally-Off E-Mode GaN

Retrieved on: 
Wednesday, September 6, 2023
Engineering, Semiconductor, Consumer Electronics, Technology, Batteries, Manufacturing, Hardware, Blockchain, SCCL, Business development, Energy industry, Overalls, UPSE, Marketing, Physics, JEDEC, Silicon, SVP, Gallium nitride, MOSFET, Cryptocurrency, Transformer, Transphorm, Computing

Transphorm, Inc. (Nasdaq: TGAN), a global leader in robust GaN power semiconductors, announced the publication of its latest white paper titled The Fundamental Advantages of D-Mode GaN in Cascode Configuration.

Key Points: 
  • Transphorm, Inc. (Nasdaq: TGAN), a global leader in robust GaN power semiconductors, announced the publication of its latest white paper titled The Fundamental Advantages of D-Mode GaN in Cascode Configuration.
  • The paper provides a brief tutorial on the inherent benefits delivered by a cascode (normally-off) d-mode GaN platform.
  • The paper demonstrates several key advantages achieved by the normally-off d-mode GaN platform including:
    Easily operating at higher power levels: higher saturation current with Transphorm d-mode, whereas e-mode must be paralleled to achieve same amps (which causes reduced power density and reliability).
  • Normally-off d-mode GaN or e-mode,” said Philip Zuk, SVP, Business Development and Marketing, Transphorm.

India Coal Mining Market Report 2022: Featuring Coal India & Singareni Collieries - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 27, 2022
Coal, Energy, Natural Resources, Mining, Minerals, Tax, Development, Singareni Collieries Company, Coal India, Ministry, Fiscal, Industry, Government, CIL, Indian government response to the COVID-19 pandemic, SCCL, Ministry of Coal, Coal mining, Reserve, Product forecasting, Steel, Coal, Iron ore, Coal

The "India Coal Mining Market Analysis including Reserves, Production, Production Forecasts, Operating, Developing and Exploration Assets, Key Players and the Fiscal Regime including Taxes and Royalties, 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "India Coal Mining Market Analysis including Reserves, Production, Production Forecasts, Operating, Developing and Exploration Assets, Key Players and the Fiscal Regime including Taxes and Royalties, 2021-2026" report has been added to ResearchAndMarkets.com's offering.
  • This report provides comprehensive coverage on India's Coal mining industry with historical and forecast data on coal production, reserves by country, and world coal prices.
  • Of the total, about 93.9%, or 811.9Mt, is expected to be thermal coal, and the remaining will be metallurgical coal.
  • Currently, there are 36 captive and commercial coal mines operating in India that produced 27.7Mt of coal in Q2 2022 - reporting a 79% y-o-y growth.

Global $250+ Bn Syngas & Derivatives Markets, Competition, Forecast and Opportunities, 2017-2021 & 2022-2027 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 18, 2022
Energy, Other Energy, Oil, Gas, Carbon, SQ, Consumption, Aviation biofuel, Polymer, Linde plc, Government, Alcohol, Coal, Electricity, Atmosphere of Earth, Review, Ammonia, Attention, Leigh Creek Energy, CAGR, Singareni Collieries Company, Pyrolysis, Climate, Coal India, Methanol, CIL, JV, Praxair, SCCL, Chemical industry, Industry, CO, Air Products & Chemicals, Fertilizer, Acid, Application, Competition, Greenhouse, Research, Gasoline, 2021 Essex County Council election, Fermentation, CHP, Hydrogen, Metabolism, Derivatives market, Methane, CO2, Ethanol

Global Syngas & Derivatives Market stood at USD248.89 billion in 2021 and is expected to grow at a CAGR of 6.27% during the forecast period due to increasing use of syngas in chemical industry and syngas' use as a clean alternative to fossil fuel.

Key Points: 
  • Global Syngas & Derivatives Market stood at USD248.89 billion in 2021 and is expected to grow at a CAGR of 6.27% during the forecast period due to increasing use of syngas in chemical industry and syngas' use as a clean alternative to fossil fuel.
  • The governments of different nations are adopting several actions to reduce greenhouse gases, which are one of the key reasons behind global warming.
  • To enhance their market share, companies in the global syngas and derivatives industry are investing in inorganic growth techniques.
  • Company Profiles: Detailed analysis of the major companies present in Global Syngas & Derivatives Market.

NICE Recognizes Innovators in Driving Frictionless Experiences, Unveiling CX Excellence Award Winners at Interactions Live 2022

Retrieved on: 
Thursday, May 26, 2022
Software, Networks, Internet, Professional Services, Data Management, Technology, Other Communications, Other Professional Services, Marketing, Human Resources, Communications, Other Technology, Cloud, CX, Company, Private Securities Litigation Reform Act, Showcase (retailer), U.S. Securities and Exchange Commission, Enlightenment, SCCL, PSCU, Blues Interaction – Live in Japan 1986, Motivation, IAG, County, Automation, Tripadvisor, NICE, Â, COVID-19, Marketing, Artificial intelligence, Workforce, Efficiency, NICE Ltd., Fifth Third Bank, Forward-looking statement, Technology, Organization, Risk, Adoption, Friction, Banco BMG, SEC, Growth, Year, Trimble, Disney Streaming Services, NPS, CEO, Customer service, Retail, Pfizer

NICE (Nasdaq: NICE) today announced the winners of its CX Excellence Awards 2022.

Key Points: 
  • NICE (Nasdaq: NICE) today announced the winners of its CX Excellence Awards 2022.
  • The CX Excellence Award winners demonstrated remarkable results in one of six categories:
    Best Cloud Implementation Celebrating the flawless deployment of next-gen, cloud-based technology that demonstrated business impact.
  • Best CX Innovation Honoring the adoption of innovative artificial intelligence, analytics or automation that drove digital fluency and transformation as well as business results.
  • www.nice.com
    Trademark Note: NICE and the NICE logo are trademarks or registered trademarks of NICE Ltd. All other marks are trademarks of their respective owners.

Ribon Therapeutics Announces Presentations at the American Association for Cancer Research 2022 Annual Meeting

Retrieved on: 
Monday, April 11, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Inflammation, Cancer, Therapy, Genome, Lung, SCCL, AACR, American Association, Enzyme, Neoplasm, Cellular senescence, Immunity, Immune system, Association, American Association for Cancer Research, Biology, Autophagy, Patient, Disease, Pembrolizumab, Pharmaceutical industry, Vaccine, Medical imaging

Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced that an oral presentation and poster presentation for RBN-2397, the Companys lead development candidate, was presented today, April 11, 2022, at the American Association for Cancer Research (AACR) Annual Meeting 2022 taking place in New Orleans, Louisiana.

Key Points: 
  • Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced that an oral presentation and poster presentation for RBN-2397, the Companys lead development candidate, was presented today, April 11, 2022, at the American Association for Cancer Research (AACR) Annual Meeting 2022 taking place in New Orleans, Louisiana.
  • RBN-2397 is a small molecule inhibitor of PARP7 being evaluated in multiple clinical trials for the treatment of cancer.
  • RBN-2397 is an orally available small molecule inhibitor of PARP7 being developed for the treatment cancer.
  • Ribon Therapeutics is a clinical stage biotechnology company developing therapeutics targeting novel enzyme families activated under cellular stress conditions that contribute to disease.

Ribon Therapeutics Announces Initiation of Phase 1b/2 Study of RBN-2397 in Combination with Pembrolizumab in Patients with Squamous Cell Carcinoma of the Lung

Retrieved on: 
Tuesday, March 29, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Inflammation, Cancer, Therapy, Genome, Lung, SCCL, Enzyme, Neoplasm, ICI, Biology, ICIS, Patient, Disease, Pembrolizumab, Large-cell lung carcinoma, Pharmaceutical industry

The initiation of the Phase 1b/2 study of RBN-2397 with pembrolizumab will enable us to further understand the potential utility of this combination therapy.

Key Points: 
  • The initiation of the Phase 1b/2 study of RBN-2397 with pembrolizumab will enable us to further understand the potential utility of this combination therapy.
  • The RBN-2397- pembrolizumab combination is anticipated to drive activated T cells into tumors with the potential to overcome resistance to ICIs.
  • PARP7 is overexpressed in a number of tumors, including squamous cell carcinoma of the lung, or SCCL, which represents approximately 30% of all non-small cell lung cancers.
  • Ribon Therapeutics is a clinical stage biotechnology company developing therapeutics targeting novel enzyme families activated under cellular stress conditions that contribute to disease.

Ribon Therapeutics, a Clinical Stage Biotechnology Company Targeting Stress Support Pathways in Cancer and Inflammation, Announces CEO Transition for Its Next Phase of Growth

Retrieved on: 
Thursday, February 17, 2022
Research, Genetics, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, ISCB Senior Scientist Award, NIBR, Ministry of Education (Malaysia), Patient, Family, Biomedical Research, Cancer, NAD, Takeda Oncology, Scripps Research, Biotechnology, Company, Inflammation, Science, Achievement, SCCL, Enzyme, Lung, R, Business development, Coronavirus Scientific Advisory Board (Turkey), Therapy, Institute, SAB, Partnership, Biology, BD, Novartis Institute for Tropical Diseases, Advanced Accelerator Applications, Medicine, Board, Flagship Pioneering, Disease, Research, Multimedia, Medicinal chemistry, History of Indian Institutes of Technology, Program, University, Management, Pharmaceutical industry, Technology, Novartis, Director

On behalf of the Board of Directors, I sincerely thank Vicky for her many contributions to the Company.

Key Points: 
  • On behalf of the Board of Directors, I sincerely thank Vicky for her many contributions to the Company.
  • I look forward to a collaborative and productive relationship with Vicky and the organization at Ribon to shepherd the company through its next phase of growth.
  • I am pleased to welcome Prakash to Ribon at this important time for the Company, said Dr. Richon.
  • Ribon Therapeutics is a clinical stage biotechnology company developing therapeutics targeting novel enzyme families activated under cellular stress conditions that contribute to disease.

Ribon Therapeutics Named a “Fierce 15” Biotech Company by Fierce Biotech

Retrieved on: 
Monday, September 27, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Biotechnology, Therapy, Inflammation, Society, NAD, Cancer, Patient, Annual general meeting, SCCL, Biology, American Society of Clinical Oncology, Managing editor, ASCO, Medicine, Ribon, Disease, Enzyme, Industry, Lung, Fine chemical, Pharmaceutical industry

Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced it has been named by Fierce Biotech as one of 2021s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.

Key Points: 
  • Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced it has been named by Fierce Biotech as one of 2021s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.
  • We are thrilled to be recognized by Fierce Biotech among the industrys leading innovators, reflecting the potential of our novel pipeline and approach.
  • Speaking with this years class of Fierce 15 winners showed us that not even a global pandemic can stop incredible innovations in medicine.
  • Ribon Therapeutics is a clinical stage biotechnology company developing therapeutics targeting novel enzyme families activated under cellular stress conditions that contribute to disease.

O-RAN ALLIANCE Broadens Its Industry Collaboration With ETSI, Announces Its 3rd Whitepaper, and 4th Release of Open Software

Retrieved on: 
Monday, August 16, 2021
Data Management, Commercial Building & Real Estate, Technology, Construction & Property, Architecture, Telecommunications, Software, Networks, Audio, Video, Mobile, Wireless, Hardware, Ericsson, European Telecommunications Satellite Organization, Linux Foundation, SMO, Ecosystem, Environment, CEO, RAN, OAM, Samsung, SCCL, Radio access network, Technology, TSDSI, Deutsche Telekom, Automation, National Medal of Technology and Innovation, Partnership, Research, Software, SVP, Near, 3GPP, Research Academic Computer Technology Institute, Architecture, Efficiency, ETSI, Samsung Electronics, Linux, XApps, OSC, Telecommunication, Adoption, Industry, Solution, Foundation, Rapp, Corporation, Online shopping, Risk management, Mobile phone, Rail transport

On May 27, 2021, the O-RAN ALLIANCE signed a cooperation agreement with the European Telecommunications Standards Institute (ETSI).

Key Points: 
  • On May 27, 2021, the O-RAN ALLIANCE signed a cooperation agreement with the European Telecommunications Standards Institute (ETSI).
  • O-RAN ALLIANCE shares with ETSI a common objective to perform and promote regional and international standardization for 3GPP based technologies.
  • It expresses mutual interest in cooperation to grow open interfaces and the open RAN ecosystem in the India subcontinent region.
  • To deep-dive into the D release and to get the open software, please visit the O-RAN Software Community website .